Holen Sie sich die Stockscreener-App
1.30
2.36%
0.03
Handel nachbörslich:
1.29
-0.01
-0.77%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SAVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1.27
Offen:
$1.2
24-Stunden-Volumen:
1.56M
Relative Volume:
0.75
Marktkapitalisierung:
$62.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.22M
KGV:
-0.942
EPS:
-1.38
Netto-Cashflow:
$-82.44M
1W Leistung:
-21.21%
1M Leistung:
-51.49%
6M Leistung:
-95.20%
1J Leistung:
-93.65%
1-Tages-Spanne:
$1.1702
$1.31
1-Wochen-Bereich:
$1.1702
$1.63
52-Wochen-Spanne:
$1.1702
$42.20
Cassava Sciences Inc Stock (SAVA) Company Profile
Firmenname
Cassava Sciences Inc
Sektor
Branche
Telefon
512-501-2444
Adresse
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Vergleichen Sie SAVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
1.30 | 62.80M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-27 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-01-10 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Cassava Sciences Inc Aktie (SAVA) Neueste Nachrichten
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
SAVA stock touches 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa
SAVA stock touches 52-week low at $1.34 amid market challenges - Investing.com Australia
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - Yahoo Finance
After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs - Being Patient
Is the Future Bleak for SAVA Stock Following Another Setback? - Yahoo Finance
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - MSN
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful - MSN
Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus - MSN
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer’s drug By Reuters - Investing.com
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study - MSN
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Zacks Investment Research
Cassava ends Alzheimer’s program after simufilam fails again - The Pharma Letter
Cassava ends simufilam Alzheimer’s programme after second Phase III failure - Yahoo Finance
Rodman & Renshaw maintains Sell rating on Cassava Sciences stock By Investing.com - Investing.com South Africa
SAVA stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
Sector Update: Health Care Stocks Fall Late Afternoon - TradingView
Sector Update: Health Care - MarketScreener
Rodman & Renshaw maintains Sell rating on Cassava Sciences stock - Investing.com India
Top Midday Decliners - MarketScreener
Cassava Sciences Stock: Alzheimer Drug Fails, Program Terminated - Sharewise
Cassava Drops 19% Pre-Market After Decision to End Alzheimer's Program - Yahoo Finance
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam - BioSpace
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop - Benzinga
Cassava ends work on Alzheimer’s drug; Alumis gets $40M upfront from Kaken - Endpoints News
Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study - NewsBreak: Local News & Alerts
Cassava stock down as Alzheimer’s program ends (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences shuts down Alzheimer's programshares plummet - Marketscreener.com
SAVA stock touches 52-week low at $2.15 amid market challenges - Investing.com Australia
Cassava Sciences' Phase 3 Study of Simufilam Showed No Benefit for Alzheimer's Patients - MarketScreener
Cassava to discontinue development of Alzheimer’s disease drug - KFGO
Cassava Sciences ends Alzheimer’s treatment development after unsuccessful trials By Investing.com - Investing.com UK
Cassava Sciences stock tumbles after Alzheimer’s drug fails key study By Investing.com - Investing.com Canada
Cassava to discontinue development of Alzheimer's disease drug - MarketScreener
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data - GlobeNewswire
Cassava Sciences Reports Topline Phase 3 Refocus-Alz Data - MarketScreener
Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSAVA - ACCESS Newswire
Cassava Sciences: Downside From Alzheimer's Results Still Possible Despite New Developments - Seeking Alpha
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Cassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Finanzdaten der Cassava Sciences Inc-Aktie (SAVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):